Trial Profile
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2021
Price :
$35
*
At a glance
- Drugs Idebenone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms SIDEROS
- Sponsors Santhera Pharmaceuticals
- 06 Oct 2020 According to a Santhera Pharmaceuticals media release, In connection with this decision, Santhera intends to start a restructuring process, aligning its operations to focus on progressing vamorolone for DMD, lonodelestat for cystic fibrosis and other lung diseases and its discovery-stage gene therapy approach for congenital muscular dystrophy.
- 06 Oct 2020 Primary endpoint has not been met. (Change From Baseline in Forced Vital Capacity percent predicted (FVC %p) at Week 78), according to a Santhera Pharmaceuticals media release.
- 06 Oct 2020 According to a Santhera Pharmaceuticals media release, the company will hold a conference call to discuss the update from the study on 6th October.